Pages that link to "Q51034795"

The following pages link to Cristina Ramo-Tello (Q51034795):

Displaying 25 items.

• Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus (Q36827205) (← links)
• Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients. (Q36919825) (← links)
• Myelin peptides in multiple sclerosis. (Q37459184) (← links)
• Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses (Q38425076) (← links)
• A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. (Q38442625) (← links)
• Defining secondary progressive multiple sclerosis (Q38843046) (← links)
• Myelitis: Differences between multiple sclerosis and other aetiologies. (Q40993238) (← links)
• Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen (Q41168849) (← links)
• Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients. (Q42491880) (← links)
• Analysis of the pain in multiple sclerosis patients. (Q44166600) (← links)
• Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project. (Q45182486) (← links)
• Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. (Q46180976) (← links)
• The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (Q46704299) (← links)
• Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates (Q47618323) (← links)
• Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. (Q47639943) (← links)
• Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. (Q48607199) (← links)
• Monitoring CD49d receptor occupancy: A method to optimize and personalize natalizumab therapy in multiple sclerosis patients. (Q48669278) (← links)
• Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients. (Q50673650) (← links)
• Beneficial effect of tolerogenic dendritic cells pulsed with MOG autoantigen in experimental autoimmune encephalomyelitis. (Q51034724) (← links)
• Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. (Q53085945) (← links)
• Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses (Q57601791) (← links)
• Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients (Q61656600) (← links)
• Specific T-cell proliferation to myelin peptides in relapsing-remitting multiple sclerosis (Q61656610) (← links)
• Hepatitis tóxica tras tratamiento concomitante con interferón beta y aloe vera en un paciente con esclerosis múltiple: a propósito de un caso (Q62534979) (← links)
• Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment (Q92186974) (← links)